Marc Blondel

List of Publications by Year in Descending Order

66 papers	2,227 citations	24 h-index	45 g-index
77 ext. papers	2,559 ext. citations	7.5 avg, IF	4.22 L-index

#	Paper	IF	Citations
66	The different activities of RNA G-quadruplex structures are controlled by flanking sequences. *Life Science Alliance*, **2022**, 5,	5.8	3
65	Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation. *Neurotherapeutics*, **2021**, 18, 1137-1150	6.4	2
64	Long-Term Fipronil Treatment Induces Hyperactivity in Female Mice. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	6
63	An Overview of In Vivo and In Vitro Models for Autosomal Dominant Polycystic Kidney Disease: A Journey from 3D-Cysts to Mini-Pigs. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
62	Artemisinin and its derivatives target mitochondrial c-type cytochromes in yeast and human cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2020**, 1867, 118661	4.9	5
61	The importance of naturally attenuated SARS-CoV-2in the fight against COVID-19. *Environmental Microbiology*, **2020**, 22, 1997-2000	5.2	35
60	Quadruplex-interacting compounds for regulating the translation of the Epstein□Barr virus nuclear antigen 1 (EBNA1) mRNA: A new strategy to prevent and treat EBV-related cancers. *Annual Reports in Medicinal Chemistry*, **2020**, 243-286	1.6	1
59	Mechanism of cystathionine-□synthase inhibition by disulfiram: The role of bis(N,N-diethyldithiocarbamate)-copper(II). *Biochemical Pharmacology*, **2020**, 182, 114267	6	10
58	Sneaking Out for Happy Hour: Yeast-Based Approaches to Explore and Modulate Immune Response and Immune Evasion. *Genes*, **2019**, 10,	4.2	4
57	A yeast-based screening assay identifies repurposed drugs that suppress mitochondrial fusion and mtDNA maintenance defects. *DMM Disease Models and Mechanisms*, **2019**, 12,	4.1	6
56	Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA. *European Journal of Medicinal Chemistry*, **2019**, 178, 13-29	6.8	17
55	Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides. *Nucleic Acids Research*, **2019**, 47, 3086-3100	20.1	19
54	Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a. *Human Molecular Genetics*, **2019**, 28, 1561-1577	5.6	21
53	EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers. *Cancers*, **2018**, 10,	6.6	33
52	Guidelines and recommendations on yeast cell death nomenclature. *Microbial Cell*, **2018**, 5, 4-31	3.9	96
51	In Cellulo Protein-mRNA Interaction Assay to Determine the Action of G-Quadruplex-Binding Molecules. *Molecules*, **2018**, 23,	4.8	12
50	The double life of the ribosome: When its protein folding activity supports prion propagation. *Prion* , **2017**, 11, 89-97	2.3	7

49	Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2017**, 1864, 2297-2307	4.9	6
48	Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA. *Nature Communications*, **2017**, 8, 16043	17.4	58
47	A yeast model for the mechanism of the Epstein-Barr virus immune evasion identifies a new therapeutic target to interfere with the virus stealthiness. *Microbial Cell*, **2017**, 4, 305-307	3.9	12
46	p53, p63 and p73 in the wonderland of. *Oncotarget*, **2017**, 8, 57855-57869	3.3	10
45	Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation. *Scientific Reports*, **2016**, 6, 32117	4.9	15
44	The dominant-negative interplay between p53, p63 and p73: A family affair. *Oncotarget*, **2016**, 7, 69549-69564	3.3	27
43	Yeast as a system for modeling mitochondrial disease mechanisms and discovering therapies. *DMM Disease Models and Mechanisms*, **2015**, 8, 509-26	4.1	83
42	The long-lasting love affair between the budding yeast Saccharomyces cerevisiae and the Epstein-Barr virus. *Biotechnology Journal*, **2015**, 10, 1670-81	5.6	10
41	Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers. *Journal of Pathology*, **2015**, 235, 334-41	9.4	21
40	Using yeast to model calcium-related diseases: example of the Hailey-Hailey disease. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2014**, 1843, 2315-21	4.9	8
39	Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost 2-adrenergic receptor agonistic activity. *ACS Chemical Neuroscience*, **2014**, 5, 1075-82	5.7	22
38	Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles. *European Journal of Medicinal Chemistry*, **2014**, 82, 363-71	6.8	10
37	A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus. *DMM Disease Models and Mechanisms*, **2014**, 7, 435-44	4.1	11
36	Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. *Nature Communications*, **2014**, 5, 5585	17.4	18
35	Meeting report: 3(rd) Meeting of the Biosensor Workgroup of the GDR2588. *Biotechnology Journal*, **2014**, 9, 178-9	5.6	
34	The antiprion compound 6-aminophenanthridine inhibits the protein folding activity of the ribosome by direct competition. *Journal of Biological Chemistry*, **2013**, 288, 19081-9	5.4	22
33	The toll-like receptor agonist imiquimod is active against prions. *PLoS ONE*, **2013**, 8, e72112	3.7	21
32	Flirting with CFTR modifier genes at happy hour. *Genome Medicine*, **2012**, 4, 98	14.4	3

31	Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding. *Biochimie*, **2011**, 93, 1047-54	4.6	19
30	The various facets of the protein-folding activity of the ribosome. *Biotechnology Journal*, **2011**, 6, 668-73	5.6	19
29	Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. *EMBO Molecular Medicine*, **2011**, 3, 35-49	12	34
28	A yeast-based assay identifies drugs active against human mitochondrial disorders. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 11989-94	11.5	60
27	Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography. *Bioconjugate Chemistry*, **2010**, 21, 279-88	6.3	12
26	Consequences of the pathogenic T9176C mutation of human mitochondrial DNA on yeast mitochondrial ATP synthase. *Biochimica Et Biophysica Acta - Bioenergetics*, **2010**, 1797, 1105-12	4.6	43
25	Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities. *PLoS ONE*, **2009**, 4, e7376	3.7	13
24	Mitochondrial ATP synthase disorders: molecular mechanisms and the quest for curative therapeutic approaches. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2009**, 1793, 186-99	4.9	88
23	Polyunsaturated fatty acids inhibit PI3K activity in a yeast-based model system. *Biotechnology Journal*, **2009**, 4, 1190-7	5.6	15
22	Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models. *Infectious Disorders - Drug Targets*, **2009**, 9, 31-9	1.1	8
21	Guanabenz, an alpha2-selective adrenergic agonist, activates Ca2+-dependent chloride currents in cystic fibrosis human airway epithelial cells. *European Journal of Pharmacology*, **2008**, 592, 33-40	5.3	13
20	Tools for the study of ribosome-borne protein folding activity. *Biotechnology Journal*, **2008**, 3, 1033-40	5.6	12
19	Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. *PLoS ONE*, **2008**, 3, e1981	3.7	90
18	Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs. *PLoS ONE*, **2008**, 3, e2174	3.7	58
17	Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography. *Biotechnology Journal*, **2007**, 2, 68-75	5.6	47
16	Antiprion drugs as chemical tools to uncover mechanisms of prion propagation. *Prion*, **2007**, 1, 48-52	2.3	13
15	A yeast-based assay to isolate drugs active against mammalian prions. *Methods*, **2006**, 39, 72-7	4.6	41
14	Using budding yeast to screen for anti-prion drugs. *Biotechnology Journal*, **2006**, 1, 58-67	5.6	28

13	Evaluation of CDK Inhibitor Selectivity. *Enzyme Inhibitors Series*, **2006**, 103-119		5
12	An expeditious synthesis of 6-aminophenanthridines. *Tetrahedron Letters*, **2005**, 46, 3725-3727	2	14
11	Degradation of Hof1 by SCF(Grr1) is important for actomyosin contraction during cytokinesis in yeast. *EMBO Journal*, **2005**, 24, 1440-52	13	98
10	Cytotoxicity of diatom-derived oxylipins in organisms belonging to different phyla. *Journal of Experimental Biology*, **2004**, 207, 2935-46	3	76
9	Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. *Oncogene*, **2004**, 23, 4400-12	9.2	81
8	A single step synthesis of 6-aminophenanthridines from anilines and 2-chlorobenzonitriles. *Tetrahedron*, **2004**, 60, 4705-4708	2.4	18
7	Control of nutrient-sensitive transcription programs by the unconventional prefoldin URI. *Science*, **2003**, 302, 1208-12	33.3	139
6	Isolation of drugs active against mammalian prions using a yeast-based screening assay. *Nature Biotechnology*, **2003**, 21, 1075-81	44.5	154
5	The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. *EMBO Journal*, **2000**, 19, 5362-75	13	138
4	Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. *EMBO Journal*, **2000**, 19, 6085-97	13	102
3	Isolation and characterization of HRT1 using a genetic screen for mutants unable to degrade Gic2p in saccharomyces cerevisiae. *Genetics*, **2000**, 155, 1033-44	4	20
2	Nuclear export of Far1p in response to pheromones requires the export receptor Msn5p/Ste21p. *Genes and Development*, **1999**, 13, 2284-300	12.6	80
1	G2 cyclins are required for the degradation of G1 cyclins in yeast. *Nature*, **1996**, 384, 279-82	50.4	41